Development and Preliminary Validation of a Tool to Assess Barriers and Facilitators to Participation in Adjuvant Endocrine Therapy Switch Trials
Silvia Belloni(IRCCS Humanitas Research Hospital), Rita De Sanctis(Humanitas University), Alberto Zambelli, Cristina Arrigoni(University of Pavia), Mariangela Gaudio(Humanitas University), Rosario Caruso(University of Milan), Paola Tiberio(Fondazione IRCCS Istituto Nazionale dei Tumori), Alice Silvia Brera(Policlinico San Matteo Fondazione), Flavia Jacobs(Fondazione IRCCS Istituto Nazionale dei Tumori), Armando Santoro(IRCCS Humanitas Research Hospital), Chiara Giacon(Policlinico San Matteo Fondazione), Emanuela Mencaglia(IRCCS Humanitas Research Hospital), Rosalba Torrisi(IRCCS Humanitas Research Hospital), C. Benvenuti
Cited by 0
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532